TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
16.16 USD
-0.17 (-1.04%)
16.16 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to TAK. TAK was compared to 191 industry peers in the Pharmaceuticals industry. TAK scores excellent on profitability, but there are concerns on its financial health. TAK has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
- TAK had positive earnings in the past year.
- TAK had a positive operating cash flow in the past year.
- Each year in the past 5 years TAK has been profitable.
- TAK had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- TAK has a Return On Assets of 0.23%. This is in the better half of the industry: TAK outperforms 78.01% of its industry peers.
- TAK has a better Return On Equity (0.46%) than 79.58% of its industry peers.
- With a decent Return On Invested Capital value of 1.87%, TAK is doing good in the industry, outperforming 79.06% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for TAK is significantly below the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROIC | 1.87% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
1.3 Margins
- Looking at the Profit Margin, with a value of 0.75%, TAK is in the better half of the industry, outperforming 78.01% of the companies in the same industry.
- TAK's Profit Margin has improved in the last couple of years.
- TAK has a Operating Margin of 8.46%. This is amongst the best in the industry. TAK outperforms 80.10% of its industry peers.
- TAK's Operating Margin has improved in the last couple of years.
- The Gross Margin of TAK (64.60%) is better than 74.35% of its industry peers.
- In the last couple of years the Gross Margin of TAK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% |
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TAK is creating some value.
- TAK has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, TAK has more shares outstanding
- The debt/assets ratio for TAK has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.23, we must say that TAK is in the distress zone and has some risk of bankruptcy.
- TAK has a Altman-Z score (1.23) which is comparable to the rest of the industry.
- TAK has a debt to FCF ratio of 5.04. This is a neutral value as TAK would need 5.04 years to pay back of all of its debts.
- TAK has a Debt to FCF ratio of 5.04. This is amongst the best in the industry. TAK outperforms 83.25% of its industry peers.
- A Debt/Equity ratio of 0.61 indicates that TAK is somewhat dependend on debt financing.
- TAK's Debt to Equity ratio of 0.61 is on the low side compared to the rest of the industry. TAK is outperformed by 68.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 1.23 |
ROIC/WACC1.16
WACC1.62%
2.3 Liquidity
- TAK has a Current Ratio of 1.36. This is a normal value and indicates that TAK is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of TAK (1.36) is worse than 73.82% of its industry peers.
- TAK has a Quick Ratio of 1.36. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
- TAK has a worse Quick ratio (0.76) than 84.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
- TAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.38%.
- TAK shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.20% yearly.
- The Revenue has decreased by -2.84% in the past year.
- TAK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.84% yearly.
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
3.2 Future
- The Earnings Per Share is expected to grow by 43.97% on average over the next years. This is a very strong growth
- The Revenue is expected to decrease by -0.03% on average over the next years.
EPS Next Y83.65%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
EPS Next 5YN/A
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 230.86, the valuation of TAK can be described as expensive.
- TAK's Price/Earnings ratio is a bit cheaper when compared to the industry. TAK is cheaper than 75.39% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.38. TAK is valued rather expensively when compared to this.
- Based on the Price/Forward Earnings ratio of 26.46, the valuation of TAK can be described as expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of TAK indicates a somewhat cheap valuation: TAK is cheaper than 73.82% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.29. TAK is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 230.86 | ||
| Fwd PE | 26.46 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, TAK is valued cheaper than 87.43% of the companies in the same industry.
- 92.67% of the companies in the same industry are more expensive than TAK, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.75 | ||
| EV/EBITDA | 10.67 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of TAK may justify a higher PE ratio.
- A more expensive valuation may be justified as TAK's earnings are expected to grow with 43.97% in the coming years.
PEG (NY)2.76
PEG (5Y)12.03
EPS Next 2Y68.19%
EPS Next 3Y43.97%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 3.86%, TAK has a reasonable but not impressive dividend return.
- TAK's Dividend Yield is rather good when compared to the industry average which is at 0.40. TAK pays more dividend than 96.86% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.85, TAK pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.86% |
5.2 History
- The dividend of TAK has a limited annual growth rate of 1.18%.
- TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
- TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
- TAK pays out 935.06% of its income as dividend. This is not a sustainable payout ratio.
- The dividend of TAK is growing, but earnings are growing more, so the dividend growth is sustainable.
DP935.06%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
16.16
-0.17 (-1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/dmh
Earnings (Next)01-28 2026-01-28
Inst Owners47.21%
Inst Owner Change-0.03%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap51.05B
Revenue(TTM)4.42T
Net Income(TTM)33.08B
Analysts74.44
Price Target16.52 (2.23%)
Short Float %0.37%
Short Ratio4.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.86% |
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP935.06%
Div Incr Years2
Div Non Decr Years3
Ex-Date03-30 2026-03-30 (100)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.49%
Min EPS beat(2)-121.92%
Max EPS beat(2)38.94%
EPS beat(4)1
Avg EPS beat(4)-35.42%
Min EPS beat(4)-121.92%
Max EPS beat(4)38.94%
EPS beat(8)4
Avg EPS beat(8)-31.47%
EPS beat(12)6
Avg EPS beat(12)-33.69%
EPS beat(16)7
Avg EPS beat(16)-40.61%
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-6.76%
Max Revenue beat(2)-6.04%
Revenue beat(4)0
Avg Revenue beat(4)-3.84%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)-0.48%
Revenue beat(8)4
Avg Revenue beat(8)3.03%
Revenue beat(12)7
Avg Revenue beat(12)3.44%
Revenue beat(16)11
Avg Revenue beat(16)3.69%
PT rev (1m)1.64%
PT rev (3m)-6.4%
EPS NQ rev (1m)1.04%
EPS NQ rev (3m)21.49%
EPS NY rev (1m)-6.66%
EPS NY rev (3m)-18.71%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)1.51%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-0.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 230.86 | ||
| Fwd PE | 26.46 | ||
| P/S | 1.83 | ||
| P/FCF | 8.75 | ||
| P/OCF | 6.73 | ||
| P/B | 1.13 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.67 |
EPS(TTM)0.07
EY0.43%
EPS(NY)0.61
Fwd EY3.78%
FCF(TTM)1.85
FCFY11.43%
OCF(TTM)2.4
OCFY14.86%
SpS8.84
BVpS14.28
TBVpS-3.2
PEG (NY)2.76
PEG (5Y)12.03
Graham Number4.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROCE | 3.03% | ||
| ROIC | 1.87% | ||
| ROICexc | 1.99% | ||
| ROICexgc | 8.07% | ||
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% | ||
| FCFM | 20.88% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 37.3% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | 3.04 | ||
| Cash Conversion | 107.4% | ||
| Profit Quality | 2788.5% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | 1.23 |
F-Score6
WACC1.62%
ROIC/WACC1.16
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
EPS Next Y83.65%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A
EBIT growth 1Y-31.07%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year435.35%
EBIT Next 3Y77.31%
EBIT Next 5YN/A
FCF growth 1Y613.62%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y24.54%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the fundamental rating for TAK stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status for TAK stock?
ChartMill assigns a valuation rating of 5 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
What is the profitability of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for TAK stock?
The Price/Earnings (PE) ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 230.86 and the Price/Book (PB) ratio is 1.13.
How financially healthy is TAKEDA PHARMACEUTIC-SP ADR?
The financial health rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 3 / 10.